Researchers reported early clinical efficacy for a high-avidity BCMA CAR T-cell therapy (MDC-CAR-BCMA001) in relapsed or refractory systemic light chain (AL) amyloidosis. In a seven-patient cohort, overall response reached 86%, including three complete remissions with negative measurable residual disease, alongside manageable cytokine release syndrome that resolved in all cases with tocilizumab and/or dexamethasone.